Impaired intestinal barrier function is thought to be a common major factor in food hypersensitivity, inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and colitis-associated cancer (CAC). Joan Heath and colleagues found that Gpa33–/– mice, which do not express the intestinal epithelium-specific cell surface glycoprotein A33 (GPA33), exhibited increased intestinal permeability and hypersensitivity to food antigens. Such alterations worsened upon exposure to dextran sodium sulphate (DSS), an intestinal luminal irritant, and led to the development of colitis in Gpa33–/– mice. Prior administration of azoxymethane (AOM; a colon-specific mutagen) induced CAC in DSS-treated Gpa33–/– mice but not in Gpa33–/– mice treated with AOM alone. Interestingly, human gene expression data showed that GPA33 RNA expression is reduced in the inflamed bowel of CD- and UC-affected individuals. Collectively, these data suggest a role for GPA33 in intestinal barrier function, which influences susceptibility to inflammatory intestinal pathologies. Gpa33–/– mice could be used to test the restoration of barrier function as a strategy to treat and prevent such pathologies. Page
Skip Nav Destination
Article navigation
August 2015
Virtual Meeting - Developmental Disorders: From Mechanism to Treatment
A collaboration between the Development and Disease Models & Mechanisms journal teams, this virtual Meeting will unite developmental biologists, human geneticists and clinical researchers to focus on building bridges from bench to clinic. Register your interest and find out more.
High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition
Vitamin B1 is shown to prevent nutrition-induced fatty liver in our current Editor’s choice by Hay Davir and his colleagues, when they use sheep as a large-animal model for studying the disease.
Find out more in an interview with the paper's first authors, Mugagga Kalyesubula and Ramgopal Mopuri.
Upcoming grant deadlines
Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on targeting the RAS pathway.
Social media
